The biotech’s ultrasound platform could help overcome two major barriers holding back genetic medicine: size and repeat dosing.
What if the biggest obstacle in gene therapy isn’t the gene, but getting it where it needs to go? For all the excitement surrounding genetic medicine, one problem has followed the field for decades.
Scientists have become remarkably good at identifying disease-causing genes. They’ve become increasingly sophisticated at designing therapies to replace, silence or edit them. However, moving those treatments into the right cells safely and effectively remains one of biotech’s toughest engineering challenges.
That challenge is right at SonoThera’s newly announced $125 million Series B financing round, led by Vida Ventures and joined by a roster of investors that includes Johnson & Johnson, Bayer, Otsuka, UCB Ventures, ARK Invest and several existing backers [1].
The South San Francisco-based company will use the funding to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD), while continuing to develop a platform designed to make genetic medicines safer, more targeted and, crucially, repeatable. And while neither disease sits squarely within the longevity sector, the technology behind them could eventually have implications that reach much further.
Modern gene therapies typically rely on modified viruses to carry genetic material into cells. These viral carriers have enabled some remarkable breakthroughs, but they come with constraints. They can only transport relatively small pieces of genetic cargo, and because the immune system learns to recognize them, patients often get just one shot. Repeat dosing can become difficult or impossible.
For longevity researchers, this limitation matters. Many of the therapies envisioned for aging and age-related decline may require repeated interventions over time. Some may also involve larger genetic payloads than today’s delivery systems can comfortably handle. In other words, the field needs better vehicles to deliver.
SonoThera believes it may have one. Rather than relying on viruses, the company combines standard clinical ultrasound with microscopic gas-filled bubbles known as microbubbles. Once these bubbles circulate through the bloodstream, ultrasound can be used to temporarily open pathways into cells, allowing genetic material to enter.
Imagine briefly opening a gate exactly where you need it, delivering the cargo and then closing the gate again. Because the approach avoids viral delivery, it may also avoid some of the immune responses that have historically limited repeat treatment.
Why Duchenne is relevant to aging
Duchenne muscular dystrophy is a devastating genetic disease caused by the absence of functional dystrophin, a protein that helps protect muscle fibers from damage. At first glance, it seems far removed from longevity science, but if you look closer, the biological overlap is difficult to ignore.
Without dystrophin, muscles enter a relentless cycle of injury and repair. The body’s regenerative machinery works overtime trying to keep up. Eventually, those repair systems begin to wear down. Inflammation becomes chronic, regenerative capacity declines and healthy muscle is gradually replaced by scar-like fibrotic tissue and fat.
The process mirrors many of the mechanisms researchers associate with aging itself. The difference is speed. What normally unfolds across decades during aging can occur much earlier and much more aggressively in Duchenne patients. In effect, the disease acts as an accelerated model of tissue degeneration, chronic inflammation and regenerative exhaustion. That makes it a valuable proving ground for technologies designed to restore function to damaged tissues.
A kidney disease with familiar longevity biology
SonoThera’s second lead indication, ADPKD, offers another intriguing connection to the aging field. The disease is driven by inherited genetic mutations that cause fluid-filled cysts to grow throughout the kidneys. Yet the progression of those cysts depends heavily on biological pathways that longevity researchers know well.
Among them is mTOR, one of the most extensively studied pathways in aging biology. mTOR acts as a kind of cellular growth regulator, helping cells decide when to build, grow and consume resources. Dysregulated mTOR activity has been linked not only to age-related disease but also to the expansion of kidney cysts in ADPKD.
It’s one reason why interventions commonly discussed in longevity circles, including rapamycin, caloric restriction and ketogenic dietary approaches, have attracted attention as potential strategies to slow disease progression.
The boundaries between rare disease research and aging research are becoming increasingly blurred as scientists uncover shared biological mechanisms beneath seemingly unrelated conditions. Investors are betting on more than two diseases. The scale and composition of the financing round may ultimately be the most telling part of the story.
Major pharmaceutical companies already have substantial investments in genetic medicine. Their participation suggests growing recognition that delivery technology could become one of the defining competitive advantages of the next decade.
“We are grateful to have the support of this exceptional group of new and existing investors who share our vision of expanding the potential of genetic medicines,” said Dr Kenneth Greenberg, cofounder and CEO of SonoThera.
Vida Ventures Managing Director Rajul Jain echoed that view, saying the platform “has the potential to unlock opportunities in diseases with significant unmet need that have been previously inaccessible to other genetic medicine approaches.”
The financing follows preclinical results showing targeted delivery across multiple tissues, including skeletal muscle, heart, liver, kidney and brain, as well as successful delivery of both DNA and RNA payloads. The company expects to initiate its first clinical trial in DMD in 2027.
The bigger longevity story
The longevity field often focuses on breakthrough molecules, rejuvenation factors and novel interventions, yet some of the most consequential advances may arrive in a less glamorous form: infrastructure.
A therapy cannot extend healthy lifespan if it cannot reliably reach the cells it is designed to help. That brings us back to the question at the beginning of this story. What if the biggest obstacle in gene therapy isn’t the gene itself?
SonoThera’s $125 million raise suggests a growing number of investors believe the answer may lie in delivery. The company still has a long road ahead, and preclinical promise does not always translate into clinical success. However, if its platform proves capable of delivering larger genetic payloads repeatedly and safely, it could help remove one of the most persistent bottlenecks in genetic medicine.
For longevity biotechnology, the real opportunity lies in a new way of getting future therapies where they need to go.
